Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielNo recent work listed

Alexander Arlt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6160-1059; OpenAlex author ID A5044651811. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 16

  1. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Last author DOI 10.1038/s41419-022-05535-9↗
  2. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  3. Get rid of pancreatic cancer by inhibiting garbage disposal?: Comment on "UAE1 Inhibition mediates the unfolded protein response, DNA damage and caspase-depend… First author DOI 10.1016/j.tranon.2020.100968↗
  4. Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †. Co-author DOI 10.3390/cancers12030581↗
  5. Coming in the Air: Hypoxia Meets Epigenetics in Pancreatic Cancer. First author DOI 10.3390/cells9112353↗
  6. NF-κB Dependent Chemokine Signaling in Pancreatic Cancer. Last author DOI 10.3390/cancers11101445↗
  7. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  8. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines. Last author DOI 10.3390/ijms19061661↗
  9. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Last author DOI 10.1016/j.bbamcr.2017.02.005↗
  10. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Co-author DOI 10.1038/onc.2016.344↗
  11. Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma. Co-author DOI 10.1080/13543784.2016.1240167↗
  12. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Last author DOI 10.1038/cddis.2014.417↗
  13. Targeting apoptosis pathways in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2010.10.015↗
  14. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased protea… Co-author DOI 10.1038/onc.2012.493↗
  15. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. First author DOI 10.1016/j.diff.2011.11.013↗
  16. The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer. Co-author DOI 10.1038/oncsis.2012.35↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Claudia Geismann · 8 shared papers, 2013–2023 · strength 1.01
  2. H. Schäfer · 11 shared papers, 2012–2023 · strength 0.89
  3. Günter Schneider · 8 shared papers, 2014–2023 · strength 0.70
  4. Christian Schneeweis · 3 shared papers, 2018–2023 · strength 0.35
  5. Zonera Hassan · 4 shared papers, 2017–2022 · strength 0.30
  6. Christoph Röcken · 2 shared papers, 2020–2023 · strength 0.29
  7. Jan-Paul Gundlach · 2 shared papers, 2019–2023 · strength 0.27
  8. Maximilian Reichert · 3 shared papers, 2017–2022 · strength 0.24
  9. Oliver Holger Krämer · 3 shared papers, 2017–2022 · strength 0.24
  10. Roland Rad · 3 shared papers, 2017–2022 · strength 0.24
  11. Matthias Wirth · 3 shared papers, 2017–2022 · strength 0.24
  12. Dieter Saur · 3 shared papers, 2017–2022 · strength 0.24
  13. Susanne Sebens · 3 shared papers, 2013–2020 · strength 0.20
  14. Leontine Sandforth · 1 shared paper, 2020 · strength 0.13
  15. Nourhane Ammar · 1 shared paper, 2020 · strength 0.13
  16. Sandra Diersch · 1 shared paper, 2022 · strength 0.12
  17. Chiara Falcomatà · 1 shared paper, 2022 · strength 0.12
  18. Marian Grade · 1 shared paper, 2022 · strength 0.12
  19. Daniele Lucarelli · 1 shared paper, 2022 · strength 0.12
  20. Lukas Krauß · 1 shared paper, 2022 · strength 0.12
  21. Carolin Schneider · 1 shared paper, 2022 · strength 0.12
  22. Elisabeth Heßmann · 1 shared paper, 2022 · strength 0.12
  23. Roland Michael Schmid · 2 shared papers, 2017–2018 · strength 0.12
  24. Bence Sipos · 2 shared papers, 2014–2017 · strength 0.09
  25. Holger Kalthoff · 2 shared papers, 2012 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.